Intelligent Bio Solutions Secures Strategic Manufacturing Partnership to Cut Production Costs by 40%
核心洞察
Intelligent Bio Solutions announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd. (搜索) to scale production of its Intelligent Fingerprinting Drug Screening Reader (搜索).
The collaboration is expected to deliver annual production cost savings of more than 40%, translating to an expected improvement of approximately 20 percentage points in gross margin.
Syrma Johari's manufacturing capacity is approximately four times INBS' current capacity, positioning the company to efficiently support anticipated demand as it scales commercial operations.
Intelligent Bio Solutions Inc. (NASDAQ: INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech Ltd. (搜索) to support and scale production of its Intelligent Fingerprinting Drug Screening Reader (搜索), with the collaboration expected to deliver significant operational and financial benefits including annual production cost savings of more than 40%.
The partnership represents a strategically significant milestone for the medical technology company, which develops intelligent, rapid, non-invasive testing solutions. INBS anticipates the cost savings will translate to an expected improvement of approximately 20 percentage points in gross margin compared with its previous manufacturing arrangement.
Enhanced Manufacturing Capacity and Global Reach
Syrma Johari's manufacturing capacity is approximately four times INBS' current capacity, positioning the company to efficiently support anticipated demand as it scales commercial operations. The partnership strengthens INBS' global manufacturing strategy, reducing reliance on a single supplier and building greater resilience into its supply chain.
Syrma Johari brings over 45 years of experience as a globally recognized medical device engineering and manufacturing organization. The company operates 14 manufacturing locations and four design and innovation centres across India, Europe, and the United States, with a combined plant area of over 1.1 million square feet.
"Partnering with Syrma Johari is a strategically significant milestone for our business," said Callistus Sequeira, Vice President of Global Quality and Operations at Intelligent Bio Solutions. "Its global footprint, manufacturing excellence, and proven track record in regulated medical devices make it an outstanding partner as we scale production of our Drug Screening Reader."
Regulatory Compliance and Quality Standards
Syrma Johari is fully certified to ISO 13485, MDSAP, FDA, TUV SUD, and GMP standards, ensuring world-class compliance and quality in medical device manufacturing. The company's extensive regulatory and quality-assurance capabilities align with INBS' global expansion plans, providing end-to-end quality systems, regulatory documentation support, and compliance processes designed to meet requirements of major jurisdictions including the U.S., Europe, Canada, the UK, and key Asia-Pacific markets.
The partnership's scale, vertical integration, and export-oriented operating model enable high-quality production while creating efficiencies in sourcing, tooling, testing, and logistics. Syrma Johari's expertise in electronics, mechanical assembly, PCB manufacturing, functional testing, and clean-room processes positions them to produce INBS' fingerprint drug-screening reader to a consistently high standard while delivering cost advantages over time.
Preparing for U.S. Market Entry
The collaboration creates flexibility as the company prepares for anticipated future demand across multiple regions and planned U.S. market entry in 2026. Syrma Johari is preparing to open its new medical-grade plastics manufacturing facility in India in January 2026, further expanding its capabilities to meet growing global demand and provide international clients with a strategically located, reliable manufacturing alternative in Asia.
"Partnering with Intelligent Bio Solutions is an exciting opportunity to apply our engineering strength, manufacturing scale, and quality systems to a breakthrough technology with global potential," said Pankaj Wadke, Head International Sales & Business Development at Syrma Johari MedTech Ltd. (搜索) "We look forward to supporting INBS as they expand access to this disruptive, non-invasive drug-screening platform."
Technology Platform and Market Applications
The Intelligent Fingerprinting Drug Screening System is designed as a hygienic and cost-effective system that screens for recent use of drugs commonly found in the workplace, including opiates (搜索), cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, the technology serves as a valuable tool for employers in safety-critical industries.
The company's current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners. The fingerprint sweat analysis technology has potential for broader applications in additional fields beyond workplace drug screening.